Zoetis Inc. $ZTS Shares Sold by Dakota Wealth Management

Dakota Wealth Management lowered its stake in shares of Zoetis Inc. (NYSE:ZTS) by 9.8% during the third quarter, HoldingsChannel.com reports. The institutional investor owned 55,558 shares of the company’s stock after selling 6,063 shares during the period. Dakota Wealth Management’s holdings in Zoetis were worth $8,129,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in the stock. Savvy Advisors Inc. raised its position in Zoetis by 54.0% in the second quarter. Savvy Advisors Inc. now owns 3,177 shares of the company’s stock worth $495,000 after acquiring an additional 1,114 shares in the last quarter. CIBC Asset Management Inc increased its position in shares of Zoetis by 4.3% in the third quarter. CIBC Asset Management Inc now owns 251,495 shares of the company’s stock valued at $36,745,000 after buying an additional 10,434 shares in the last quarter. Mitsubishi UFJ Trust & Banking Corp increased its position in shares of Zoetis by 6.5% in the third quarter. Mitsubishi UFJ Trust & Banking Corp now owns 295,482 shares of the company’s stock valued at $43,235,000 after buying an additional 18,040 shares in the last quarter. Ninety One UK Ltd raised its stake in shares of Zoetis by 19.6% during the 3rd quarter. Ninety One UK Ltd now owns 1,119,132 shares of the company’s stock worth $163,751,000 after buying an additional 183,686 shares during the last quarter. Finally, Quilter Plc grew its stake in Zoetis by 10.2% in the 3rd quarter. Quilter Plc now owns 438,959 shares of the company’s stock valued at $64,228,000 after acquiring an additional 40,615 shares during the last quarter. 92.80% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

A number of brokerages have issued reports on ZTS. JPMorgan Chase & Co. cut their target price on shares of Zoetis from $230.00 to $200.00 and set an “overweight” rating for the company in a research report on Wednesday, November 5th. HSBC set a $140.00 price target on Zoetis in a research note on Wednesday, December 10th. Bank of America raised their target price on shares of Zoetis from $135.00 to $140.00 and gave the stock a “neutral” rating in a research report on Friday, February 13th. KeyCorp initiated coverage on shares of Zoetis in a research report on Thursday, November 20th. They set a “sector weight” rating for the company. Finally, Stifel Nicolaus lowered their price objective on shares of Zoetis from $140.00 to $130.00 and set a “hold” rating for the company in a research note on Tuesday, November 18th. Five equities research analysts have rated the stock with a Buy rating, seven have assigned a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, the stock currently has a consensus rating of “Hold” and an average price target of $152.91.

Zoetis Trading Down 2.3%

NYSE ZTS opened at $125.77 on Tuesday. The firm has a market capitalization of $53.09 billion, a price-to-earnings ratio of 20.89, a PEG ratio of 1.97 and a beta of 0.96. The company has a debt-to-equity ratio of 2.71, a quick ratio of 1.94 and a current ratio of 3.03. Zoetis Inc. has a one year low of $115.25 and a one year high of $177.00. The company’s 50 day moving average price is $125.50 and its 200 day moving average price is $134.48.

Zoetis (NYSE:ZTS) last released its quarterly earnings data on Thursday, February 12th. The company reported $1.48 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.40 by $0.08. The company had revenue of $2.39 billion during the quarter, compared to analyst estimates of $2.36 billion. Zoetis had a net margin of 28.24% and a return on equity of 62.02%. The business’s quarterly revenue was up 3.0% compared to the same quarter last year. During the same quarter in the prior year, the business earned $1.40 earnings per share. Zoetis has set its FY 2026 guidance at 7.000-7.100 EPS. On average, sell-side analysts predict that Zoetis Inc. will post 6.07 EPS for the current year.

Zoetis Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, June 2nd. Shareholders of record on Monday, April 20th will be paid a dividend of $0.53 per share. The ex-dividend date is Monday, April 20th. This represents a $2.12 annualized dividend and a yield of 1.7%. Zoetis’s dividend payout ratio is presently 35.22%.

Zoetis Profile

Zoetis Inc (NYSE: ZTS) is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company’s offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.

Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.